Two intra-peritoneal injections of anti-DLL4 were given at the dose rate of 10 mg/kg body weight once in 2 weeks to our recently developed T1D mouse model (Imam et al., 2019, 2020, 2021; Imam and Jaume, 2020). This evidence concerns the gene DLL4 and type 1 diabetes mellitus.